CMS Biosimilars Rule: Rulemaking Malpractice

May 26, 2016

  by Kenneth Fisher, MD Nephrologist, ASBM Advisory Board Member Biologic medicines are one of the most powerful tools physicians have to treat patients with serious conditions like cancer, rheumatoid arthritis, hepatitis, and multiple sclerosis. Copies of these therapies, called biosimilars, are becoming available in the U.S., and offer patients new treatment options, potentially at […]

Read More

The Evolution of Good Policy: An Educator’s Perspective

May 20, 2016

  By Philip Schneider, MS, FASHP ASBM Advisory Board Chair Having spent 40 years educating students, legislators, patients, and others about medications and pharmacy practice, I’ve learned that the key to changing minds is usually to get people to see things from a new, different angle. For example, as states grapple with how to handle […]

Read More

70 Stakeholder Groups Call on the FDA, Urging Distinguishable, Meaningful Suffixes for Biosimilars

May 11, 2016

WASHINGTON, DC—In a letter to the FDA this week, a 70-group coalition of healthcare stakeholders including patient and provider organizations and others urged the use of distinguishable, meaningful suffixes for biosimilars. The letter to Leah Christl, Ph.D., FDA’s associate director for therapeutic biologics, comes on the heels of FDA’s departure from a meaningful to random […]

Read More